|
"shan ys"的相关文件
显示项目 46-55 / 133 (共14页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2021-09 |
A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer
|
Chiang, NJ;Bai, LY;Huang, CJ;Chen, SC;Hsiao, CF;Shan, YS;Su, YY;Chen, L;Chen, MH |
| 國家衛生研究院 |
2021-07-15 |
No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol
|
Shan, YS;Chen, LT;Wu, CH;Chang, YF;Lee, CT;Chiang, NJ;Chao, YJ;Yen, CJ;Tsai, HJ;Huang, HE;Tsai, CR;Weng, YL;Yang, HC;Liu, HC;Chang, JS |
| 國家衛生研究院 |
2021-05 |
High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial
|
Pen, SL;Shan, YS;Hsiao, CF;Liu, TW;Chen, JS;Ho, CL;Chou, WC;Hsieh, RK;Chen, LT;Ch'ang, HJ |
| 國家衛生研究院 |
2021-05 |
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma
|
Chiang, NJ;Shan, YS;Bai, LY;Li, CP;Chen, JS;Yang, SH;Kuo, YC;Chao, Y;Hsieh, YY;Kao, HF;Hsiao, CF;Chen, LT |
| 國家衛生研究院 |
2021-04-12 |
An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan
|
Chang, JS;Chen, LT;Shan, YS;Chu, PY;Tsai, CR;Tsai, HJ |
| 國家衛生研究院 |
2021-03-26 |
A multi-mode Wnt- and stemness-regulatory module dictated by FOXM1 and ASPM isoform I in gastric cancer[Erratum:Gastric Cancer. 2021 Jan 29;Article in Press.]
|
Hsu, CC;Liao, WY;Chang, KY;Chan, TS;Huang, PJ;Chiang, CT;Shan, YS;Cheng, LH;Liao, TY;Tsai, KK |
| 國家衛生研究院 |
2021-01-29 |
A multi-mode Wnt- and stemness-regulatory module dictated by FOXM1 and ASPM isoform I in gastric cancer
|
Hsu, CC;Liao, WY;Chang, KY;Chan, TS;Huang, PJ;Chiang, CT;Shan, YS;Cheng, LH;Liao, TY;Tsai, KK |
| 國家衛生研究院 |
2021-01-13 |
Development of possible next line of systemic therapies for gemcitabine-resistant biliary tract cancers: A perspective from clinical trials
|
Chiang, NJ;Chen, LT;Shan, YS;Yeh, CN;Chen, MH |
| 中山醫學大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study
|
Chiu, TJ; Su, YY; Yang, SH; Li, CP; Bai, LY; Chiang, NJ; Chuang, SC; Shan, YS; Chan, DC; Chen, LT; Yen, CJ; Peng, CM; Chen, YY; Chen, JS; Chou, WC |
| 國家衛生研究院 |
2020-11-13 |
The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: Real-world experience in a Taiwanese cohort [Erraturm: Scientific Reports. 2020 May 4;10:Article number 7420.]
|
Su, YY;Chiang, NJ;Tsai, HJ;Yen, CJ;Shan, YS;Chen, LT |
显示项目 46-55 / 133 (共14页)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每页显示[10|25|50]项目
|
